{"url_path":"/sec/bglc/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1737523/0001477932-26-003242-index.html","accession_number":"0001477932-26-003242","cik":"0001737523","ticker":"BGLC","issuer_name":"BioNexus Gene Lab Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/1737523/0001477932-26-003242-index.html","primary_entity_key":"0001737523","primary_entity_name":"BioNexus Gene Lab Corp"},"word_count":281,"has_tables":true,"body_markdown":"**Item 6. Exhibits.**\n\n \n\n**Exhibit**\n\n \n\n**Description**\n\n \n\n \n\n \n\n[31.1](bglc_ex311.htm)\n\n \n\n[Certification of the Company’s Principal Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*](bglc_ex311.htm)\n\n \n\n \n\n \n\n[31.2](bglc_ex312.htm)\n\n \n\n[Certification of the Company’s Principal Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*](bglc_ex312.htm)\n\n \n\n \n\n \n\n[32.1](bglc_ex321.htm)\n\n \n\n[Certification of the Company’s Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002+](bglc_ex321.htm)\n\n \n\n \n\n \n\n[32.2](bglc_ex322.htm)\n\n \n\n[Certification of the Company’s Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002+](bglc_ex322.htm)\n\n \n\n \n\n \n\n101.INS\n\n \n\nInline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).*\n\n \n\n \n\n \n\n101.SCH\n\n \n\nInline XBRL Taxonomy Extension Schema Document.*\n\n \n\n \n\n \n\n101.CAL\n\n \n\nInline XBRL Taxonomy Extension Calculation Linkbase Document.*\n\n \n\n \n\n \n\n101.DEF\n\n \n\nInline XBRL Taxonomy Extension Definition Linkbase Document.*\n\n \n\n \n\n \n\n101.LAB\n\n \n\nInline XBRL Taxonomy Extension Labels Linkbase Document.*\n\n \n\n \n\n \n\n101.PRE\n\n \n\nInline XBRL Taxonomy Extension Presentation Linkbase Document.*\n\n \n\n \n\n \n\n104\n\n \n\nCover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).*\n\n______________ \n\n* Filed herewith.\n\n \n\n** Previously filed or furnished.\n\n \n\n+ Furnished herewith.\n\n \n\n \n\n44\n\n*Table of Contents*\n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n**BioNexus Gene Lab Corp.**\n\n \n\n \n\n*/s/ Su-Leng Tan Lee*\n\nSu-Leng Tan Lee\n\n \n\nChief Executive Officer \n\n(Principal Executive Officer)\n\n \n\n \n\n \n\n*/s/ Set Fui Chong*\n\n \n\nSet Fui Chong\n\n \n\nChief Financial Officer \n\n(Principal Financial and Accounting Officer)\n\n \n\n \n\nMay 15, 2026\n\n \n\n \n\n45"}